Embryo TransferPhase 1NCT02213029
A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban
A Phase 1 study testing Epelsiban, Oxytocin and Ortho-Cylcen (21)® tablet in people with Embryo Transfer, run by GlaxoSmithKline at 2 sites in United States.
Trial summary
This multi-cohort phase I study is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of oxytocin and to evaluate epelsiban (GSK557296) potential to reduce subendometrial contractractility induced by oxytocin in healthy female subjects. Read more about this study
- Who is it for?
- Ages 18 to 35 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Embryo Transfer
- What is being tested?
- Epelsiban, Oxytocin and Ortho-Cylcen (21)® tablet
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 33 participants
- Where
- 2 sitesUnited States
- Study dates
- 28 Aug 2014to 7 Feb 2016
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 35 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- For ultrasound training cohort
- Female volunteers of childbearing potential; with a negative pregnancy test as determined by human chorionic gonadotropin (hCG) testing at screening and prior to study initiation.
- Age between 18 and 35 years old (inclusive).
- Body weight >=50 kilograms (kg) and body mass index (BMI) within the range 18-30 kg/meter (m)^2 (inclusive).
- Normal ovarian and uterine anatomy as assessed by transvaginal ultrasonography.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Show all 15Show fewer
- Is in good physical and mental health as determined by a responsible and experienced physician, based on a medical evaluation including medical history, and physical examination.
- For Cohorts 1, 2A, 2B, 2C, 3
- Female volunteers of childbearing potential; with a negative pregnancy test as determined by hCG testing at screening and prior to study initiation.
- Agrees to use one of the contraception methods for 2 weeks prior to the start of study to minimize the risk of pregnancy. Female subjects must agree to use contraception until at least 48 hours have passed after the last dose of study drug. OR has only same-sex partners, when this is her preferred and usual lifestyle. Oral contraceptive (OC) pill naive or have discontinued OC at least 2 months prior to study entry.
- Age between 18 and 35 years old.
- Body weight >=50 kg and BMI within the range 18-30 kg/m^2 (inclusive).
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form as signed consent form; and is in good physical and mental health as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or exclusion criteria, outside the reference range for the population being studied may be included only if the Investigator in consultation with the GlaxoSmithKline (GSK) Medical Monitor if required agree and document that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Subjects with a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 milli international unit (MI)U/milliliter (mL) and estradiol <40 picogram/mL (<147 picomoles/Liter) should always be excluded from enrolment.
- based on single or averaged corrected QTc values of triplicate ECGs obtained over a brief recording period: QTc <450 milliseconds (msec); or QTc <480 msec in subjects with Bundle Branch Block.
Who cannot join
- For Training Cohort
- Ultrasonographic evidence of uterine anomalies, including but not limited to intramural or submucosal leiomyomas (fibroids) cysts, endometrial polyps, American Society for Reproductive Medicine (ASRM) Class I-VI uterine malformations or intrauterine fluid collections.
- Pregnancy (suspected or diagnosed) or lactation.
- Has had a prior partial or total hysterectomy or tubal ligation.
- Currently using and intrauterine device (IUD) for any reason.
- History or suspicion of drug or alcohol abuse. Criteria Based Upon Medical Histories For Training Cohort
Show all 29Show fewer
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >7 drinks. One drink is equivalent to 12 grams of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
- Criteria Based Upon Diagnostic Assessments For Training Cohort
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- A positive pre-study drug/alcohol/; and.
- A positive test for human immune virus (HIV) antibody. For Cohorts 1, 2A, 2B, 2C, 3
- Female with an abnormal obstetric profile (average durations <27 days or > 31 days;Any contraindication for oral contraception use; Is using hormone replacement therapy (HRT); Ultrasonographic evidence of ovarian dysfunction, such as Polycystic Ovary Syndrome (PCOS) or ovarian anomalies such as dermoid or hemorrhagic cysts; Ultrasonographic evidence of uterine anomalies, including but not limited to intramural or submucosal leiomyomas (fibroids) cysts, endometrial polyps, ASRM Class I-VI uterine malformations or intrauterine fluid collections.
- Pregnancy (suspected or diagnosed) or lactation.
- Has had a prior partial or total hysterectomy or tubal ligation.
- Has had prior surgical procedures to the cervix (cryoablation, loop electrical excision procedure [LEEP] or other similar procedures).
- Currently using an IUD for any reason.
- Potential volunteers who are at high risk of developing complications while taking oral contraceptives will not be entered into the study in accordance with normal standards of good clinical practice.
- History or suspicion of drug or alcohol abuse. Criteria Based Upon Medical Histories For Cohorts 1, 2, 3
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of >7 drinks. One drink is equivalent to 12 grams of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- History of hypertension, use of an anti-hypertensive, or any systolic blood pressure >=140 millimeter of mercury (mmHg) or diastolic blood pressure >=90 mmHg.
- Criteria Based Upon Diagnostic Assessments For Cohorts 1, 2, 3
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- A positive pre-study drug/alcohol/cotinine screen.
- A positive test for HIV antibody. Other Criteria
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
Trial locations and contacts
2 sites in 1 country.
United States2 sites
GSK Investigational Site
Baltimore, Maryland, 21225
GSK Investigational Site
Glendale, California, 91206
About this study
Official title: Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin
This multi-cohort phase I study is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of oxytocin and to evaluate epelsiban (GSK557296) potential to reduce subendometrial contractractility induced by oxytocin in healthy female subjects. Additionally tissues concentrations of epelsiban will be determined from endometrial tissue biopsies. Data from this study will inform the identification of the doses of epelsiban to be used in future in-vitro fertilization (IVF) clinical studies. Expected number of subjects to be randomized are: Cohort 1- 10 subjects, Cohort 2a- 10 subjects for each epelsiban arm 25 milligrams (mg), 200mg, 5 for placebo, Cohort 2b- 10 subjects per arm with dose to be determined, cohort 3- 6 subjects. Cohorts 1 and 2 will be double blind (sponsor unblinded) placebo controlled cohorts. Cohort 3 will be an open label cohort, cohort 4 will be a double blind (sponsor unblinded) placebo controlled cohort.
- Conditions
- Embryo Transfer
- Being tested
- Epelsiban, Placebo, Oxytocin, Ortho-Cylcen (21)® tablet
- Keywords
- epelsiban, pharmacokinetics, patient reported pain / discomfort, pharmacodynamics, oxytocin infusions, Uterine contractions
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
EpelsibanDrug
White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or >150mg
PlaceboDrug
White to off white oral placebo tablets to match 5mg epelsiban
OxytocinDrug
Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
Ortho-Cylcen (21)® tabletDrug
White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson
| Study group | Role | What they receive |
|---|---|---|
| Oxytocin or Placebo challenge (Cohort 1) | Experimental | Subjects will receive oxytocin and or placebo challenges as escalating intravenous (IV) infusions administered on the day of ovulation, followed by an IV bolus day 1 post ovulation, and an intramuscular (IM) injection day 2 post ovulation. The planed doses and routes of administration of oxytocin are as follows: IV infusion will be initiated at 5 milliunit/minute (mU/min) and maintained for 60 min, then the rate will be increased to 10 mU/min and maintained for 60 minutes, a final escalation to 20mU/min will be maintained for 60 minutes, after which the infusion will be stopped. For the IV bolus, a single 5 International unit (IU) IV bolus will be administered. For the IM dosing, a single 10 IU IM injection will be administered. Receives: Drug: Placebo; Drug: Oxytocin; Drug: Ortho-Cylcen (21)® tablet |
| Epelsiban or Placebo (Cohort 2) | Experimental | Subjects in Cohort 2A will receive first dose of epelsiban (25mg) or placebo after receiving initial oxytocin challenge with dose selected in Cohort 1 followed by 30 minutes washout period. Subjects will receive second dose of epelsiban (150mg) or placebo 12 hours after first dose. Based on the results of Cohort 2A, additional doses may be investigated with a new Cohort 2B (<150mg) and Cohort 2C (>200mg) with repeated oxytocin challenges. Receives: Drug: Epelsiban; Drug: Placebo; Drug: Oxytocin; Drug: Ortho-Cylcen (21)® tablet |
| Biopsy cohort (Cohort 3) | Experimental | Subjects will receive first dose of epelsiban 150mg without oxytocin challenge followed by second dose of epelsiban 150mg 24 hours after the first dose. Subsequently one hour after the second dose, subjects will undergo endometrial biopsies. Receives: Drug: Epelsiban; Drug: Ortho-Cylcen (21)® tablet |
What is being measured
The primary outcome is the main question the study is designed to answer.
The effect of the infused oxytocin dose on the time course of the frequency of endometrial contractions in Cohort 1 during the periovulatory phase
The relationship between the dose of the infused oxytocin and the time course of the frequency of endometrial contractions in Cohort 1 during the periovulatory phase (ovulation to 3-5 days post ovulation) will be assessed to establish the PD response from the oxytocin infusions and endometrial contraction rate which will provide the oxytocin infusion challenge dose to use in Cohort 2. If data permit, the effective dose 50 (ED50) of oxytocin will be also be determined. Uterine contraction rates, contractility measures, etc. will be measured by computer assisted ultrasound image analyses.
Measured: Up to Day 3
Frequency of endometrial contractions in Cohorts 2A, 2B and 2C during the periovulatory phase and 3-5 days post ovulation.
Frequency of endometrial contractions will be assessed to evaluate the dose response relationship for epelsiban with respect to its ability to reduce endometrial contractions in the study population exposed to repeated oxytocin challenges. Uterine contraction rates, contractility measures, etc. will be measured by computer assisted ultrasound image analyses.
Measured: Up to Day 2
Reduction in the frequency of subendometrial contractions in Cohorts 2 A, B and C, all during the periovulatory phase.
The reduction in the frequency of subendometrial contractions will be assessed during the periovulatory phase to investigate the PD response of epelsiban in the study population when exposed to repeated oxytocin challenges. If data permit, the infectious dose 50 (ID50) of epelsiban will also be determined. Uterine contraction rates, contractility measures, etc. will be measured by computer assisted ultrasound image analyses.
Measured: Up to Day 2
The duration of the reduction in subendometrial contractions in Cohorts 2 A, B and C, all during the periovulatory phase
The duration of the reduction in subendometrial contractions will be assessed during the periovulatory phase to investigate the PD response of epelsiban in the study population when exposed to repeated oxytocin challenges. If data permit, the infectious dose 50 (ID50) of epelsiban will also be determined. Uterine contraction rates, contractility measures, etc. will be measured by computer assisted ultrasound image analyses.
Measured: Up to Day 2
Plasma concentrations of epelsiban or metabolite and the reduction of subendometrial contraction frequency in Cohorts 2 A, B and C, all during the periovulatory phase.
The relationship between the plasma concentrations and the reduction of subendometrial contraction frequency will be assessed during the periovulatory phase to establish the PK/PD relationship between epelsiban (and/or its metabolites) and endometrial contraction rate in the study population exposed to repeated oxytocin challenges. If data permit, the maximum inhibitory effect (Imax) and IC50 of epelsiban will also be determined. Uterine contraction rates, contractility measures, etc. will be measured by computer assisted ultrasound image analyses.
Measured: PK samples will be collected at 3, 3.25, 3.5, 4, 6.5, 11, 15, 27, 31 and 39 hours post dose in cohort 2.
Secondary outcomes (15)
Frequency of endometrial and subendometrial contractility in Cohort 2.
Following parameters will be assessed: Wave period, external contractile measure, internal contractile measure and total contractile measure, wave directionality, wave amplitude and wave completeness.
Measured: Up to Day 3
Frequency of subendometrial contractility in Cohort 3
To evaluate the endometrial and subendometrial contractions following epelsiban dose in the absence of oxytocin challenges.
Measured: Up to Day 2
Number of subjects with adverse events in Cohort 1
AEs will be collected from the start of Study Treatment and until the follow-up contact.
Measured: 18 days
Number of subjects with adverse events (AEs) in Cohort 2
AEs will be collected from the start of Study Treatment and until the follow-up contact.
Measured: 17 days
Number of subjects with adverse events in Cohort 3
AEs will be collected from the start of Study Treatment and until the follow-up contact.
Measured: 16 days
Change from Baseline in laboratory parameters in Cohort 1
Laboratory parameters include: hematology, clinical chemistry, urinalysis
Measured: Baseline (screening) and upto 21 days
Change from Baseline in laboratory parameters in Cohort 2
Laboratory parameters include: hematology, clinical chemistry, urinalysis
Measured: Baseline (screening) and upto 20 days
Change from Baseline in laboratory parameters Cohort 3
Laboratory parameters include: hematology, clinical chemistry, urinalysis
Measured: Baseline (screening) and upto 19 days
Change from Baseline in vital signs in Cohort 1
Vital signs measurement include: blood pressure, pulse pressure, heart rate.
Measured: Baseline (screening) and upto 21 days
Change from Baseline in vital signs in Cohort 2
Vital signs measurement include: blood pressure, pulse pressure, heart rate.
Measured: Baseline (screening) and upto 20 days
Change from Baseline in vital signs in Cohort 3
Vital signs measurement include: blood pressure, pulse pressure, heart rate.
Measured: Baseline (screening) and upto 19 days
Change from Baseline in electrocardiogram (ECG) parameters in Cohort 1
ECG parameters include: PR, QRS, QT, and corrected QT (QTc) intervals.
Measured: Baseline (screening) and upto 21 days
Change from Baseline in ECG parameters in Cohort 2
ECG parameters include: PR, QRS, QT, and corrected QT (QTc) intervals.
Measured: Baseline (screening) and upto 20 days
Change from Baseline in ECG parameters in Cohort 3
ECG parameters include: PR, QRS, QT, and corrected QT (QTc) intervals.
Measured: Baseline (screening) and upto 19 days
Composite of PK parameters following epelsiban dosing
PK parameters will be assessed for epelsiban and its metabolite (GSK2395448). PK parameters include: maximum plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration-time curve (AUC), apparent terminal phase half-life (t1/2), renal clearance (CL).
Measured: PK samples will be collected at 3, 3.25, 3.5, 4, 6.5, 11, 15, 27, 31 and 39 hours post dose in cohort 2.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2014 (estimated)
- Study start28 Aug 2014
- Primary completion7 Feb 2016
- Study completion7 Feb 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Embryo TransferStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 33 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02213029
- Sponsor's protocol ID
- 116828
- Status last verified
- May 2017
- First submitted
- 7 Aug 2014
- Last updated
- 8 May 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin
- ClinicalTrials.gov ID
- NCT02213029
- Acronym / sponsor ID
- 116828
- Conditions
- Embryo Transfer
- Keywords
- epelsiban, pharmacokinetics, patient reported pain / discomfort, pharmacodynamics, oxytocin infusions, Uterine contractions
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 33 participants (actual)
- Lead sponsor
- GlaxoSmithKlineIndustry (pharma, biotech, devices)
- Study start
- 28 Aug 2014 (actual)
- Primary completion
- 7 Feb 2016 (actual)
- Study completion
- 7 Feb 2016 (actual)
- First posted
- 11 Aug 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This multi-cohort phase I study is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of oxytocin and to evaluate epelsiban (GSK557296) potential to reduce subendometrial contractractility induced by oxytocin in healthy female subjects. Additionally tissues concentrations of epelsiban will be determined from endometrial tissue biopsies. Data from this study will inform the identification of the doses of epelsiban to be used in future in-vitro fertilization (IVF) clinical studies. Expected number of subjects to be randomized are: Cohort 1- 10 subjects, Cohort 2a- 10 subjects for each epelsiban arm 25 milligrams (mg), 200mg, 5 for placebo, Cohort 2b- 10 subjects per arm with dose to be determined, cohort 3- 6 subjects. Cohorts 1 and 2 will be double blind (sponsor unblinded) placebo controlled cohorts. Cohort 3 will be an open label cohort, cohort 4 will be a double blind (sponsor unblinded) placebo controlled cohort.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Oxytocin or Placebo challenge (Cohort 1) | Experimental | Drug: Placebo, Drug: Oxytocin, Drug: Ortho-Cylcen (21)® tabletSubjects will receive oxytocin and or placebo challenges as escalating intravenous (IV) infusions administered on the day of ovulation, followed by an IV bolus day 1 post ovulation, and an intramuscular (IM) injection day 2 post ovulation. The planed doses and routes of administration of oxytocin are as follows: IV infusion will be initiated at 5 milliunit/minute (mU/min) and maintained for 60 min, then the rate will be increased to 10 mU/min and maintained for 60 minutes, a final escalation to 20mU/min will be maintained for 60 minutes, after which the infusion will be stopped. For the IV bolus, a single 5 International unit (IU) IV bolus will be administered. For the IM dosing, a single 10 IU IM injection will be administered. |
| Epelsiban or Placebo (Cohort 2) | Experimental | Drug: Epelsiban, Drug: Placebo, Drug: Oxytocin, Drug: Ortho-Cylcen (21)® tabletSubjects in Cohort 2A will receive first dose of epelsiban (25mg) or placebo after receiving initial oxytocin challenge with dose selected in Cohort 1 followed by 30 minutes washout period. Subjects will receive second dose of epelsiban (150mg) or placebo 12 hours after first dose. Based on the results of Cohort 2A, additional doses may be investigated with a new Cohort 2B (<150mg) and Cohort 2C (>200mg) with repeated oxytocin challenges. |
| Biopsy cohort (Cohort 3) | Experimental | Drug: Epelsiban, Drug: Ortho-Cylcen (21)® tabletSubjects will receive first dose of epelsiban 150mg without oxytocin challenge followed by second dose of epelsiban 150mg 24 hours after the first dose. Subsequently one hour after the second dose, subjects will undergo endometrial biopsies. |
Who may qualify
- Ages
- 18 to 35 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (15 listed)
- For ultrasound training cohort
- Female volunteers of childbearing potential; with a negative pregnancy test as determined by human chorionic gonadotropin (hCG) testing at screening and prior to study initiation.
- Age between 18 and 35 years old (inclusive).
- Body weight >=50 kilograms (kg) and body mass index (BMI) within the range 18-30 kg/meter (m)^2 (inclusive).
- Normal ovarian and uterine anatomy as assessed by transvaginal ultrasonography.
Key exclusion criteria (29 listed)
- For Training Cohort
- Ultrasonographic evidence of uterine anomalies, including but not limited to intramural or submucosal leiomyomas (fibroids) cysts, endometrial polyps, American Society for Reproductive Medicine (ASRM) Class I-VI uterine malformations or intrauterine fluid collections.
- Pregnancy (suspected or diagnosed) or lactation.
- Has had a prior partial or total hysterectomy or tubal ligation.
- Currently using and intrauterine device (IUD) for any reason.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| EpelsibanWhite to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or >150mg | Drug | Biopsy cohort (Cohort 3), Epelsiban or Placebo (Cohort 2) |
| PlaceboWhite to off white oral placebo tablets to match 5mg epelsiban | Drug | Epelsiban or Placebo (Cohort 2), Oxytocin or Placebo challenge (Cohort 1) |
| OxytocinOxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM). | Drug | Epelsiban or Placebo (Cohort 2), Oxytocin or Placebo challenge (Cohort 1) |
| Ortho-Cylcen (21)® tabletWhite, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson | Drug | Biopsy cohort (Cohort 3), Epelsiban or Placebo (Cohort 2), Oxytocin or Placebo challenge (Cohort 1) |
Primary outcome
The effect of the infused oxytocin dose on the time course of the frequency of endometrial contractions in Cohort 1 during the periovulatory phase
Time frame: Up to Day 3
The relationship between the dose of the infused oxytocin and the time course of the frequency of endometrial contractions in Cohort 1 during the periovulatory phase (ovulation to 3-5 days post ovulation) will be assessed to establish the PD response from the oxytocin infusions and endometrial contraction rate which will provide the oxytocin infusion challenge dose to use in Cohort 2. If data permit, the effective dose 50 (ED50) of oxytocin will be also be determined. Uterine contraction rates, contractility measures, etc. will be measured by computer assisted ultrasound image analyses.
Frequency of endometrial contractions in Cohorts 2A, 2B and 2C during the periovulatory phase and 3-5 days post ovulation.
Time frame: Up to Day 2
Frequency of endometrial contractions will be assessed to evaluate the dose response relationship for epelsiban with respect to its ability to reduce endometrial contractions in the study population exposed to repeated oxytocin challenges. Uterine contraction rates, contractility measures, etc. will be measured by computer assisted ultrasound image analyses.
Reduction in the frequency of subendometrial contractions in Cohorts 2 A, B and C, all during the periovulatory phase.
Time frame: Up to Day 2
The reduction in the frequency of subendometrial contractions will be assessed during the periovulatory phase to investigate the PD response of epelsiban in the study population when exposed to repeated oxytocin challenges. If data permit, the infectious dose 50 (ID50) of epelsiban will also be determined. Uterine contraction rates, contractility measures, etc. will be measured by computer assisted ultrasound image analyses.
The duration of the reduction in subendometrial contractions in Cohorts 2 A, B and C, all during the periovulatory phase
Time frame: Up to Day 2
The duration of the reduction in subendometrial contractions will be assessed during the periovulatory phase to investigate the PD response of epelsiban in the study population when exposed to repeated oxytocin challenges. If data permit, the infectious dose 50 (ID50) of epelsiban will also be determined. Uterine contraction rates, contractility measures, etc. will be measured by computer assisted ultrasound image analyses.
Plasma concentrations of epelsiban or metabolite and the reduction of subendometrial contraction frequency in Cohorts 2 A, B and C, all during the periovulatory phase.
Time frame: PK samples will be collected at 3, 3.25, 3.5, 4, 6.5, 11, 15, 27, 31 and 39 hours post dose in cohort 2.
The relationship between the plasma concentrations and the reduction of subendometrial contraction frequency will be assessed during the periovulatory phase to establish the PK/PD relationship between epelsiban (and/or its metabolites) and endometrial contraction rate in the study population exposed to repeated oxytocin challenges. If data permit, the maximum inhibitory effect (Imax) and IC50 of epelsiban will also be determined. Uterine contraction rates, contractility measures, etc. will be measured by computer assisted ultrasound image analyses.
15 secondary outcomes
Frequency of endometrial and subendometrial contractility in Cohort 2.
Time frame: Up to Day 3
Frequency of subendometrial contractility in Cohort 3
Time frame: Up to Day 2
Number of subjects with adverse events in Cohort 1
Time frame: 18 days
Number of subjects with adverse events (AEs) in Cohort 2
Time frame: 17 days
Number of subjects with adverse events in Cohort 3
Time frame: 16 days
Change from Baseline in laboratory parameters in Cohort 1
Time frame: Baseline (screening) and upto 21 days
Change from Baseline in laboratory parameters in Cohort 2
Time frame: Baseline (screening) and upto 20 days
Change from Baseline in laboratory parameters Cohort 3
Time frame: Baseline (screening) and upto 19 days
Change from Baseline in vital signs in Cohort 1
Time frame: Baseline (screening) and upto 21 days
Change from Baseline in vital signs in Cohort 2
Time frame: Baseline (screening) and upto 20 days
Change from Baseline in vital signs in Cohort 3
Time frame: Baseline (screening) and upto 19 days
Change from Baseline in electrocardiogram (ECG) parameters in Cohort 1
Time frame: Baseline (screening) and upto 21 days
Change from Baseline in ECG parameters in Cohort 2
Time frame: Baseline (screening) and upto 20 days
Change from Baseline in ECG parameters in Cohort 3
Time frame: Baseline (screening) and upto 19 days
Composite of PK parameters following epelsiban dosing
Time frame: PK samples will be collected at 3, 3.25, 3.5, 4, 6.5, 11, 15, 27, 31 and 39 hours post dose in cohort 2.
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2017.
- Results for study 116828 can be found on the GSK Clinical Study Register.Link provided by the sponsor.
Related trials for Embryo Transfer
Not yet recruiting
Cryopreserved Pre-embryo Transfer in a Cytokine-rich Medium Versus Hyaluronic Acid
Frozen Embryo Transfer (FET)
Active, not recruitingPhase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
Infertility (IVF Patients)
Not yet recruitingObservational study
Linzagolix in Adenomyosis and Recurrent Implantation Failure
Adenomyosis of Uterus, Implantation Failure
RecruitingPhase 2
Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle
Vaginal Dysbiosis
RecruitingPhase 2/3
Thymosin-α1 for Recurrent Implantation Failure
Recurrent Implantation Faliure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
GlaxoSmithKline
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Epelsiban, Oxytocin and Ortho-Cylcen (21)® tablet in people with Embryo Transfer, run by GlaxoSmithKline at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 8 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The effect of the infused oxytocin dose on the time course of the frequency of endometrial contractions in Cohort 1 during the periovulatory phase (time frame: Up to Day 3). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2017.